azathioprine has been researched along with amg531 in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Salama, A | 1 |
Brunet, E; Calvet, X; Garcia-Iglesias, P; MartÃnez de Sola, M | 1 |
Aboud, N; Depré, F; Mayer, B; Salama, A | 1 |
2 review(s) available for azathioprine and amg531
Article | Year |
---|---|
Current treatment options for primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Azathioprine; Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Isoantibodies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rho(D) Immune Globulin; Rituximab; Thrombocytopenia; Thrombopoietin | 2011 |
Immune thrombocytopenic purpura associated with Crohn's disease with complete response to infliximab.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azathioprine; Benzoates; Crohn Disease; Humans; Hydrazines; Immunosuppressive Agents; Infliximab; Male; Middle Aged; Pancreatitis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction | 2019 |
2 other study(ies) available for azathioprine and amg531
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Benzoates; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Dapsone; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2018 |